NCT00151788

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

A Randomized, Double-blind, Stratified, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Heterozygous Familial Hypercholesterolemia and Carotid Atherosclerosis Using Carotid Ultrasound (CUS)

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 796 (planned)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The effects of pactimibe versus placebo on the progression of atherosclerosis in the carotid arteries will be assessed using standard ultrasound techniques.

Conditions

• Atherosclerosis
• Heterozygous Familial Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Pactimibe sulfate

Timeline

• Start date: 2004-02-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-09-09
• Last updated: 2012-01-18

Locations

37 sites across 9 countries: United States, Canada, Israel, Netherlands, Norway, South Africa, Spain, Sweden, United Kingdom